



## Molecular Genomics in Brain Tumors

Guest Editors:

### Dr. Marta Mellai

1. Department of Health Sciences, Università del Piemonte Orientale "A. Avogadro", Via Solaroli 17, 28100 Novara, Italy

2. Center for Translational Research on Autoimmune and Allergic Disease (CADD), Corso Trieste 15A, 28100 Novara, Italy

### Prof. Dr. Renzo Boldorini

1. Department of Health Sciences, Università degli Studi del Piemonte Orientale "A. Avogadro", Via Solaroli 17, Novara, Italy

2. Pathology Unit, Maggiore della Carità Hospital, 28100 Novara, Italy

Deadline for manuscript submissions:

**31 July 2026**

### Message from the Guest Editors

Gliomas are frequent and malignant primary brain tumors in adults and pediatric patients. Besides several translational and clinical studies in the last few years, gliomas remain the most lethal neoplasm in the central nervous system.

This Special Issue aims to collect findings and innovations in this research field, including the molecular landscape of gliomas, the tumor microenvironment, the microbiota–gut–brain-axis, cell cross-talk, transcriptomics, epigenomics, proteomics and metabolomics studies, or therapeutics advances.

Potential topics include, but are not limited to, the following:

1. Technical advancement in gold-standard neuro-imaging procedures;
2. Advances in the molecular genetics of gliomas using next-generation techniques with implications for classification and therapy;
3. The tumor microenvironment in the discovery of new therapeutic biomarkers;
4. The microbiota–gut–brain axis;
5. Introductions, in clinics, of novel therapeutic options.

We are pleased to invite you to participate in this Special Issue by presenting original research articles, clinical studies, multi-omics analysis, or reviews, as well as new ideas and hypotheses.





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)